Efficacy and safety of low-dose oral lenalidomide in refractory cutaneous lupus erythematosus: an open series of 19 cases.
2020
Lenalidomide (LND), a synthetic thalidomide analog mainly used in haematological malignancies has proved efficient and well-tolerated in small case series of refractory Cutaneous Lupus Erythematosus (CLE). A retrospective survey of CLE patients treated with low-dose LND in three institutional Departments of Dermatology was conducted to further assess the benefit/risk ratio of this molecule in this setting (Institutional Review Board for ethical issues of University Hospital of Montpellier 2018_IRB-MTP_11-01). Primary endpoints were best overall response (BOR) obtained with initial dosage or after dose adjustment and time to achieve BOR.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
8
References
0
Citations
NaN
KQI